Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Current Deferred Revenue (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Current Deferred Revenue for 2 consecutive years, with $592000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $592000.0, compared with a TTM value of $592000.0 through Sep 2025, changed N/A, and an annual FY2018 reading of $93000.0, changed N/A over the prior year.
  • Current Deferred Revenue was $592000.0 for Q3 2025 at X4 Pharmaceuticals, down from $754000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $855000.0 in Q1 2025 and bottomed at $592000.0 in Q3 2025.